965 related articles for article (PubMed ID: 29074588)
1. GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.
Khound R; Taher J; Baker C; Adeli K; Su Q
Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2252-2259. PubMed ID: 29074588
[TBL] [Abstract][Full Text] [Related]
2. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
3. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
Ding X; Saxena NK; Lin S; Gupta NA; Anania FA
Hepatology; 2006 Jan; 43(1):173-81. PubMed ID: 16374859
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
6. Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats.
Qin B; Anderson RA; Kuzuya T; Kitaura Y; Shimomura Y
Atherosclerosis; 2012 Jun; 222(2):409-16. PubMed ID: 22546076
[TBL] [Abstract][Full Text] [Related]
7. GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice.
Taher J; Baker C; Alvares D; Ijaz L; Hussain M; Adeli K
Endocrinology; 2018 Sep; 159(9):3340-3350. PubMed ID: 30052880
[TBL] [Abstract][Full Text] [Related]
8. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters.
Bilz S; Samuel V; Morino K; Savage D; Choi CS; Shulman GI
Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E716-22. PubMed ID: 16291572
[TBL] [Abstract][Full Text] [Related]
9. Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α.
Lucero D; Miksztowicz V; Macri V; López GH; Friedman S; Berg G; Zago V; Schreier L
Clin Investig Arterioscler; 2015; 27(4):167-74. PubMed ID: 25796423
[TBL] [Abstract][Full Text] [Related]
10. SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes.
Li X; Li Y; Yang W; Xiao C; Fu S; Deng Q; Ding H; Wang Z; Liu G; Li X
J Steroid Biochem Mol Biol; 2014 Sep; 143():174-82. PubMed ID: 24565561
[TBL] [Abstract][Full Text] [Related]
11. LXRalpha activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins.
Basciano H; Miller A; Baker C; Naples M; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G323-32. PubMed ID: 19497957
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance.
Taher J; Baker CL; Cuizon C; Masoudpour H; Zhang R; Farr S; Naples M; Bourdon C; Pausova Z; Adeli K
Mol Metab; 2014 Dec; 3(9):823-33. PubMed ID: 25506548
[TBL] [Abstract][Full Text] [Related]
13. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice.
Parlevliet ET; Wang Y; Geerling JJ; Schröder-Van der Elst JP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H; Rensen PC
PLoS One; 2012; 7(11):e49152. PubMed ID: 23133675
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling.
Seo MH; Lee J; Hong SW; Rhee EJ; Park SE; Park CY; Oh KW; Park SW; Lee WY
PLoS One; 2016; 11(12):e0166913. PubMed ID: 27907035
[TBL] [Abstract][Full Text] [Related]
15. Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios.
Peter A; Cegan A; Wagner S; Lehmann R; Stefan N; Königsrainer A; Königsrainer I; Häring HU; Schleicher E
Clin Chem; 2009 Dec; 55(12):2113-20. PubMed ID: 19850634
[TBL] [Abstract][Full Text] [Related]
16. Ablation of fatty acid desaturase 2 (FADS2) exacerbates hepatic triacylglycerol and cholesterol accumulation in polyunsaturated fatty acid-depleted mice.
Hayashi Y; Lee-Okada HC; Nakamura E; Tada N; Yokomizo T; Fujiwara Y; Ichi I
FEBS Lett; 2021 Jul; 595(14):1920-1932. PubMed ID: 34008174
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling.
Qin B; Anderson RA; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2008 May; 294(5):G1120-9. PubMed ID: 18372392
[TBL] [Abstract][Full Text] [Related]
18. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia.
Quiroga AD; Li L; Trötzmüller M; Nelson R; Proctor SD; Köfeler H; Lehner R
Hepatology; 2012 Dec; 56(6):2188-98. PubMed ID: 22806626
[TBL] [Abstract][Full Text] [Related]
20. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
